Archit Organosys Limited's Board of Directors has approved a significant property acquisition from its promoter, marking an important corporate development for the Gujarat-based company. The decision was taken during a board meeting held on February 21, 2026, demonstrating the company's strategic approach to asset acquisition.

Board Meeting Details

The Board of Directors and Audit Committee of Archit Organosys Limited convened on Saturday, February 21, 2026, to deliberate on the property purchase proposal. The meeting details are outlined below:

Property Transaction Details

The board approved the purchase of immovable property situated in Bhavnagar from Shri Kandarp Krishnakant Amin, who serves as the Chairman and Whole Time Director of the company. This transaction represents a related party deal given Amin's promoter status.

Regulatory Compliance

The transaction has been structured in full compliance with SEBI regulations. The company has fulfilled its disclosure obligations under multiple regulatory frameworks:

• Regulation 30: Material events disclosure requirements
• Schedule III: Specific disclosure formats
• Regulation 23: Related party transaction regulations

The company has committed to providing additional intimation to the stock exchange once the Conveyance Deed or Sale Deed is executed, ensuring complete transparency throughout the transaction process.

Corporate Information

Archit Organosys Limited operates from its registered office at 903, 9th Floor, Venus Benecia, Near Pakwan Restaurant, Bodakdev, S. G. Highway, Ahmedabad-380054, Gujarat. The company holds CIN: L24110GJ1993PLC019941 and maintains its manufacturing unit at Survey No. 228/A, Paiki 7, Paiki 2, Village - Narmad, Bhavnagar-364313, Gujarat.

The notification was digitally signed by Kandarp Amin in his capacity as Whole-time Director on February 21, 2026, at 19:56:12 +05'30', confirming the authenticity of the corporate communication to BSE Limited.

Archit Organosys Limited has delivered impressive financial performance for the third quarter of FY26, with the company's Board of Directors approving the unaudited financial results for the quarter and nine months ended December 31, 2025, during their meeting held on February 7, 2026.

Strong Quarterly Performance

The company demonstrated robust growth in Q3FY26, with significant improvements across all major financial parameters compared to the corresponding quarter of the previous year.

The quarter-on-quarter performance also showed positive momentum, with net profit increasing from ₹153.92 lakhs in Q2FY26 to ₹243.48 lakhs in Q3FY26, marking a 58.2% sequential growth.

Nine-Month Performance Highlights

The company's nine-month performance for the period ended December 31, 2025, reflected sustained growth momentum across key metrics.

Operational and Cost Structure Analysis

The company's expense management showed mixed trends during Q3FY26. While cost of materials consumed increased to ₹1,485.34 lakhs from ₹919.56 lakhs in Q3FY25, this was offset by improved operational efficiency. Employee benefit expenses decreased to ₹181.47 lakhs compared to ₹216.25 lakhs in the corresponding quarter last year. Finance costs rose to ₹55.56 lakhs from ₹47.18 lakhs, while depreciation remained relatively stable at ₹151.74 lakhs.

Regulatory Compliance and Business Segment

Archit Organosys operates in a single segment focused on chemicals and organics, which is considered the company's only reportable business segment. The company has implemented provisions related to the New Labour Codes that became effective on November 21, 2025, recognizing defined benefit obligations based on management's assessment. The company continues monitoring the finalization of Central and State Rules and clarifications from the Government regarding various aspects of the New Labour Codes.

Financial Position and Shareholder Returns

The company maintained a stable capital structure with paid-up equity share capital of ₹2,052.07 lakhs, consisting of shares with a face value of ₹10 each. The strong earnings performance translated into improved earnings per share, with both basic and diluted EPS reaching ₹1.19 for Q3FY26 compared to ₹0.49 in the corresponding quarter of the previous year. The financial results were reviewed by the Audit Committee and approved by the Board of Directors, with statutory auditors completing the required limited review under SEBI regulations.